| 000 | 01754 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250514022628.0 | ||
| 264 | 0 | _c20020228 | |
| 008 | 200202s 0 0 eng d | ||
| 022 | _a1537-6591 | ||
| 024 | 7 |
_a10.1086/324620 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDenning, David W | |
| 245 | 0 | 0 |
_aEfficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. _h[electronic resource] |
| 260 |
_bClinical infectious diseases : an official publication of the Infectious Diseases Society of America _cMar 2002 |
||
| 300 |
_a563-71 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntifungal Agents _xadverse effects |
| 650 | 0 | 4 |
_aAspergillosis _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aPyrimidines _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTriazoles _xadverse effects |
| 650 | 0 | 4 | _aVoriconazole |
| 700 | 1 | _aRibaud, Patricia | |
| 700 | 1 | _aMilpied, Noel | |
| 700 | 1 | _aCaillot, Denis | |
| 700 | 1 | _aHerbrecht, Raoul | |
| 700 | 1 | _aThiel, Eckhard | |
| 700 | 1 | _aHaas, Andrea | |
| 700 | 1 | _aRuhnke, Markus | |
| 700 | 1 | _aLode, Hartmut | |
| 773 | 0 |
_tClinical infectious diseases : an official publication of the Infectious Diseases Society of America _gvol. 34 _gno. 5 _gp. 563-71 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1086/324620 _zAvailable from publisher's website |
| 999 |
_c11718317 _d11718317 |
||